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I
mmunotherapy has become an attrac-
tive strategy and an essential compo-
nent of a successful antitumor treat-
ment.1,2 Current immunotherapies are pri-
marily aimed at harnessing both the innate
and adaptive immune systems to initiate or
boost a strong immune response to tumors
and their antigens. On their own, however,
most immunotherapeutic approaches fall
short of initial expectations when used
against aggressive and advanced malig-
nancy.3 Evidence indicated that during the
progression, the surviving tumor cells are
able to develop several different mecha-
nisms to avoid immune recognition and
elimination,4,5 making a theoretically effi-
cient immunotherapy become offset. There-
fore, development of an effective treatment
against advanced tumors remains a major
challenge for cancer immunotherapy.
Nanotechnology has had significant im-
pact on a variety of therapeutics for de-
cades.68 Advances in materials and formu-
lation have allowed safer andmore efficient
delivery of a myriad of drugs. Targeted de-
livery ensures a specific action and reduced
systemic side effects. Nanoparticle-based
delivery systems also hold much promise
for cancer immunotherapy.912 The flexibil-
ity and specificity of nanoparticle-based
delivery systems provide an opportunity
for both targeting the immune system to
initiate a potent immune response and
targeting the tumor tissue for a local mod-
ification of the tumor microenvironment.
We have successfully developed several
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ABSTRACT Achievement of potent immunoresponses against self/tumor antigens and
effective therapeutic outcome against advanced tumors remain major challenges in cancer
immunotherapy. The specificity and efficiency of two nanoparticle-based delivery systems,
lipid-calcium-phosphate (LCP) nanoparticle (NP) and liposome-protamine-hyaluronic acid
(LPH) NP, provide us an opportunity to address both challenges. A mannose-modified LCP
NP delivered both tumor antigen (Trp 2 peptide) and adjuvant (CpG oligonucleotide) to the
dendritic cells and elicited a potent, systemic immune response regardless of the existence
or the stage of tumors in the host. This vaccine was less effective, however, against later
stage B16F10 melanoma in a subcutaneous syngeneic model. Mechanistic follow-up studies
suggest that elevated levels of immune-suppressive cytokines within the tumor microenvironment, such as TGF-β, might be responsible. We strategically
augment the efficacy of LCP vaccine on an advanced tumor by silencing TGF-β in tumor cells. The delivery of siRNA using LPH NP resulted in about 50%
knockdown of TGF-β in the late stage tumor microenvironment. TGF-β down-regulation boosted the vaccine efficacy and inhibited tumor growth by 52%
compared with vaccine treatment alone, as a result of increased levels of tumor infiltrating CD8þ T cells and decreased level of regulatory T cells.
Combination of systemic induction of antigen-specific immune response with LCP vaccine and targeted modification of tumor microenvironment with LPH
NP offers a flexible and powerful platform for both mechanism study and immunotherapeutic strategy development.
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delivery systems that meet the merits. In the present
work, we are interested in exploring their potentials to
work as an effective immunotherapeutic system against
advanced tumors under a rational combination.
Inducing a potent systemic immune response against
the tumor is the prerequisite of an efficient cancer
immunotherapy.13Wepreviously reportedanenhanced,
persistent, in vivo antigen loading and activation of
dendritic cells in response to a mannose-modified LCP
NP-based vaccine containing both tumor-specific anti-
gen and adjuvant.14 This vaccine evoked a strong in vivo
cytotoxic T lymphocyte (CTL) response against poorly
immunogenic self-antigen tyrosinase-related protein 2
(Trp2) peptide, resulting in potent antitumor effects
against melanoma in a subcutaneous xenograft model
andametastasismodel. Therefore, the LCPparticle offers
a promising platform for generating potent systemic
immune responses against tumor antigens.
During the progression, the tumor cells change the
microenvironment to impede immunotherapy. Thus,
approaches to specifically modify or normalize the
tumor microenvironment are becoming a vital compa-
nion for an effective immunotherapy. LPH NP is an-
other well-established delivery system in our lab that
has been optimized for systemic delivery of siRNA to
the tumor site with high specificity and efficiency.15
Targeted modification of tumor microenvironment
using LPH NP may allow for tumor cell-specific inter-
vention without the adverse effects and complications
from the systemic alteration.
In the present work, a spontaneous and poorly im-
munogenic B16F10 melanoma was chosen over the
artificial xenogeneic tumor models to create a realistic
model for in vivo evaluation. To test for an immu-
notherapy against advancedmelanoma, the therapeu-
tic efficacy of LCP NP-based vaccine was first evaluated
against a later stage melanoma. The systemic and local
parameters were investigated to reveal the correlation
between a compromised tumor growth inhibition
mediated by LCP vaccine and the progression of
melanoma. A strategy to augment the efficacy of LCP
vaccine was proposed and achieved by reversing the
immunosuppressive microenvironment using LPH NP.
The efficacy of the combined immunotherapies was
compared with solo treatment, and changes in tumor
microenvironment were monitored to verify the hy-
pothesis and mechanism.
RESULTS AND DISCUSSION
Immunotherapy against malignancies has been ex-
plored with effort focused on potent induction of sys-
temic responses. Several animal models have been
used for cancer vaccine development, generally using
a foreign antigen, such as E7 antigen in cervical cancer
andOVA peptide in E.G7-OVA tumor.1618 The effect of
the vaccine typically becomesmarginal under a setting
of self-antigen (when using transgenic mice), which
unfortunately represents the case for most tumor-
specific antigens. There are also notable differences in
the effects of prophylactic vaccines versus therapeutic
cancer vaccines, and advanced solid tumor models are
rarely studied to evaluate a self-antigen-based vaccine.
Here, we report an attempt to address two major chal-
lenges, self-antigen and advanced tumor, simultaneously,
through use of nanoparticle-based delivery systems.
Characterization of LCP NP and LPH NP. To improve the
efficiency of the therapeutic vaccine against the self-
antigen, Trp2 (SVYDFFVWL), we co-delivered the anti-
gen together with CpG oligonucleotides (ODN) as a
potent adjuvant by incorporating them into LCP
nanoparticles.14 LCP NP was developed previously in
our lab as a new class of intracellular delivery systems.
Formation of the LCP core requires the precipitation
of calcium phosphate in the aqueous phase of a
microemulsion system. To facilitate encapsulation,
phosphorylated serine residues were added to Trp2
peptide to interact with calcium and increase the co-
precipitation of Trp2 with calcium phosphate. The
increased hydrophilicity of the phosphorylated pep-
tide may also keep it within the aqueous phase and
further increase the chance of co-precipitation. The NP
surfacewas functionalizedwithmannose to achieve an
enhanced and prolonged cargo deposit into the lymph
nodes. The encapsulation efficiency of p-Trp2 peptide
in LCP NP was about 50%, and efficiency of CpG ODN
encapsulation was approximate 40%. The final LCP NP
were about 30 nm in diameter as determined by TEM
after negative staining (Figure 1A), slightly smaller than
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the hydrodynamic diameter (4045 nm) obtained by
dynamic light scattering. The zeta potential was about
15mV. Each component in the LCP NP is designated to
improve the stability of NP, enhance the antigen
delivery efficiency, or boost the immune response.
Absence of any component would result in a compro-
mised antitumor efficacy.14
Targeted LPH NP were previously optimized for
systemic delivery of siRNA to tumor site.15 LPH NP
are prepared through a stepwise self-assembly pro-
cess. A mixture of siRNA and HA was condensed with
protamine. The complex with slightly negative surface
charge was then coated with cationic liposome via
electrostatic interaction. Cationic liposome coated NP
was subsequently PEGylated to reduce protein binding
to evade uptake by the reticuloendothelial system,
allowing for extended circulation time in the blood. A
targeting ligand, anisamide, was added to enhance the
payload delivery to sigma receptor overexpressing
cancer cells. The final LPH-NP was about 50 nm in dia-
meter with a surface charge of 25 mV, as determined
by using Zetasizer. The decreased surface charge of
LPH-NP compared with cationic liposomes (∼50 mV)
was indicative of efficient PEGylation. TEM of LPH-NP
after uranyl-acetate staining showed a particle size
around 40 nm (Figure 1B).
Inhibition of Tumor Growth by Vaccination at Different
Stages of Tumor Progression. Previous studies indicated
that LCP vaccination at early stage (4 days after tumor
inoculation) resulted in a potent growth inhibition of
B16F10 subcutaneous tumors and lung metastases.14
In the present work, we are particularly interested in
the potential of LCP as a therapeutic vaccine for
advanced melanoma. We evaluated the therapeutic
effect of the LCP NP-based vaccine at different tumor
stages in a B16F10 melanoma model. C57BL/6 mice
were subcutaneously inoculated with B16F10 melano-
ma cells on day 0 and LCP vaccine was given on day
4 or day 13, respectively, when the tumors were at
different stages of progression. Tumor size and body
weight were monitored every 2 to 3 days for 18 days.
As shown in Figure 2, B16F10 melanoma pro-
gressed aggressively without any treatment. Tumors
reached 20 mm in one dimension on day 18, with an
average size over 2000 mm3. Compared with the
untreated control, both vaccinated groups showed a
tumor growth inhibition, but to varying extents. Con-
sistent with previous study, early vaccination (Early
vac) on day 4, when the tumors were still on early de-
velopment stage, exhibited a significant inhibition of
tumor growth (p < 0.001). Whereas in the case of late
vaccination (Late vac), as the same vaccine was given
when the tumor size had already reached 200 mm3, its
efficacy was much less potent. No decrease in body
weight was observed in any of the groups, indicating
that there is no toxicity associated with the treatments.
Slight weight gain in some groups may result from the
tumor growth.
In Vivo Cytotoxic T Lymphocyte Response after Vaccination.
Primary CTL responses are important in stopping
Figure 2. Antitumor activity of LCP vaccine against different stages of B16F10melanoma. C57BL/6micewere inoculatedwith
2 105 B16F10 cells on day 0. LCP vaccine was injected on day 4 (Early vac) and day 13 (Late vac). Tumor growth (A) and body
weight (B) were measured every 2 to 3 days for 18 days. n = 5, *P < 0. 05, **P < 0. 001. Statistical analyses were done by
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tumor growth,13 and previous studies have confirmed
that the LCP vaccine is able to elicit an antigen-specific
CTL response against Trp2 peptide. Although ad-
vanced tumors are known to be difficult to treat,
reduced efficacy of late vaccination still raises the
question of why and how could the same vaccine work
differently on the same type of tumor at different
stages? To provide a possible answer, an assay for
antigen-specific CTL responses under various condi-
tions was performed. C57BL/6 mice were inoculated
subcutaneously on day 0, and LCP vaccines were given
on day 4 or day 13, respectively. Splenocytes from
naïve mice were pulsed with Ova or Trp2 peptide and
labeled with different levels of carboxyfluorescein
succinimidyl ester (CFSE) (Ova-pulsed CFSElow, Trp2-
pulsed CFSEhigh). Seven days after vaccination, mice
were intravenously injected with a mixture containing
equal amounts of Ova-pulsed CFSElow and Trp2-pulsed
CFSEhigh. Specific lysis of Trp2-pulsed splenocytes was
analyzed using flow cytometry. As shown in Figure 3,
compared with non-tumor bearing mice (Control
(Non-tumor)), there was no detectable Trp2-specific
CTL response within the tumor-bearing mice (Control
(Tumor-bearing)), indicating that Trp2 peptide is in-
deed a self-antigen and there is an immune tolerance
to Trp2 in the tumor-bearing mice. All the mice receiv-
ing LCP vaccine showed an efficient elimination of the
Trp2-pulsed target cells, suggesting that LCP vaccine is
able to break the pre-existing immune tolerance to
Trp2 peptide. A similar percentage of specific lysis was
obtained in groups of tumor bearing mice (Early) and
non-tumor bearing mice (Non-tumor). No significant
differencewas observed between the early vaccination
(Early) group and the late vaccination (Late) group.
For a tumor/self-antigen as Trp 2 peptide, it is
mostly likely that not only the pre-existing tolerance
but also the immune suppression gained along with
the tumor progression will interfere with the immuno-
genesis. However, our in vivo CTL response study indi-
cated that LCP NP-based vaccine elicited a potent
systemic immune response regardless of the existence
and stage of tumors, ruling out the possibility that
compromised efficacy resulted from unsuccessful
induction of antigen-specific CTL response at a late
stage. This result also suggested that the nanoparticle-
based vaccine formulation was able to break both
the pre-established and acquired immune tolerance,
inducing a strong antigen-specific immune response
against advanced tumor.
Changes of Cytokine Levels within the Tumor Microenviron-
ment. Increasing evidence has demonstrated that can-
cer cells constantly alter the local microenvironment
during the progression.19 We then set to examine the
local parameters. To evade the immunosurveillance
and elimination, cancer cells usually go about generat-
ing a malignancy supportive while immune suppres-
sive microenvironment during the progression. They
are able to release some cytokines to directly suppress
Figure 3. In vivo CTL response after vaccination under various conditions. C57BL/6micewere inoculatedwith 2 105 B16F10
cells SC on day 0. LCP vaccine was given on day 4 (Early) and day 13 (Late). Target cells pulsed with Ova or Trp2 were stained
with low (Ova) or high (Trp2) concentrations of CFSE, mixed, and injected into vaccinated mice. After 18 h, splenocytes were
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the immune effective cells locally to counteract the
systemic immune response.20 To test whether the
difference of the efficacy was from the altered cytokine
levels within the tumor microenvironment, we har-
vested melanoma tumors from vaccinated mice, and
measured cytokine levels. The tumors from control
group were collected at the end point of the thera-
peutic study as well. All the tumors were inoculated
and harvested on the same day to allow a same period
of time for progression. Tumor local cytokine levels
were determined by RT-PCR (Figure 4). Compared with
control, elevated local cytokine levels were seen for all
the tested cytokines except TGF-β after early vaccina-
tion, indicating a local response occurred after treat-
ment. While tumor local TNF-R and CCL2 levels were
significant increased after early vaccination, minimal
changes were seen after late vaccination. In contrast,
the late vaccination group showed a notable increase
in TGF-β and IL-10. Since both IL-10 and TGF-β are anti-
inflammatory cytokines that have an inhibitory effect
on effector T cells, these results suggested that the up-
regulated levels of IL-10 and TGF-β might contribute
to an immune suppressive local microenvironment,
potentially the cause of the compromised effective-
ness of the vaccine.
TNF-R, IL-6, and CCL2 are pro-inflammatory cyto-
kines produced by both tumor and stromal cells
(including immune cells). The effect of these cytokines
on tumor elimination or progression is still controver-
sial. For example, high local levels of TNF-R prove to be
beneficial21 and, combined with other cytokines, such
as IL-12, can have synergistic antitumor effects.22 In
contrast, evidence also indicates that TNF-R produced
chronically at low levels may promote tumor devel-
opment.23 Since a given signaling molecule may act
through different pathways in different cell types,
opposite conclusions may be explained by different
experimental systems. In our experiments, local TNF-R,
IL-6 and CCL2 levels were elevated significantly after
early vaccination and correlated with enhanced anti-
tumor activity, suggesting that a positive local im-
mune response echoed after the systemic induction
(Figure 3). On the other hand, as an anti-inflammatory
cytokine produced by both tumor and stromal cells,
TGF-β exhibits dual functions as well on tumor pro-
gression.24 It is recognized, however, that TGF-β can
promote tumor progression by suppressing immune
effector cells, such as cytotoxic T cells and natural killer
cells, and promoting negative regulatory cells, such as
Treg cells. Our results demonstrate that the compro-
mised effects of late vaccination correlate with an
elevated TGF-β at mRNA level, confirming the negative
role of TGF-β in cancer immunotherapy.
Augmentation of the Therapeutic Efficacy of LCP Vaccine by
Down-Regulating TGF-β in the Tumor Microenvironment. On
the basis of the above observations, we proposed that
the efficacy of the LCP vaccine against advanced
melanoma could be enhanced by down-regulating
the suppressive cytokines, such as TGF-β, within the
tumor microenvironment. To test this hypothesis,
tumor-specific silencing of TGF-β was achieved by
systemic delivery of anti-TGF-β siRNA with LPH NP,
and the therapeutic efficacy of the combined treat-
ments was evaluated.
As shown in Figure 5A, treatment with anti-TGF-β
siRNA alone exhibited a modest inhibitory effect on
tumor growth, while control siRNA had no effect at all,
ruling out any effect from the delivery vehicle itself.
Though additional TGF-β silencing did not have any
effect with early vaccination (Figure 5C, Early vac
compared with LPH (TGF-β) þ Early vac, P > 0. 05), it
enhanced the efficacy of late vaccination significantly
(Figure 5D, Late vac compared with LPH (TGF-β)þ Late
vac, P < 0. 05). Notably, when combined with TGF-β
silencing, late vaccination showed a comparable effi-
cacy with early vaccination (Figure 5E, LPH (TGF-β) þ
Late vac compared with LPH (TGF-β) þ Early vac, P >
0. 05). No decrease in bodyweight was observed in any
of the groups (Figure 5B), indicating that there is no tox-
icity associated with any treatments. Down-regulation
of TGF-β within the tumor after gene silencing treat-
ment was further confirmed by RT-PCR (Figure 6).
It is reported that TGF-β can act as a tumor sup-
pressor at early stage by inhibiting tumor cell prolifera-
tion and inducing apoptosis, while its role as a tumor
promoter comes at later stage.25 We would like to
spare the tumor suppressor part of TGF-β and focus
only on the tumor promoter part. Meanwhile, from the
drug delivery perspective, since EPR (enhanced perme-
ability and retention) effect is the primary driving force
for the high accumulation of the drug in the tumor
tissue, NPs based therapy are usually administered to
the animal when palpable tumors are formed and the
leaky neo-vasculature is present in the tumor. For these
reasons, TGF-β siRNA treatment was started on day 13
when tumors had progressed to a later stage. TGF-β
siRNA alone did not show a significant effect, suggest-
ing that removal of the immune suppressor alone
was not sufficient for tumor elimination. The antitumor
Figure 4. Tumor local cytokine level after vaccination.
C57BL/6 mice were inoculated with 2  105 B16F10 cells
on day 0. LCP vaccine was given on day 4 (Early vac) or day
13 (Late vac). Mice were sacrificed on day 18, and tumors
were collected for cytokine detection using RT-PCR. n = 5,
*P < 0. 05, **P < 0. 001. Statistical analyses were done by
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activity of TGF-β inhibition is dependent on the host
immune response, while tumor associated antigens
were well tolerated without vaccination.
Strategies to disrupt the immune suppressive mi-
croenvironment have already been proposed and
tested for enhancement of anticancer effects, gener-
ally using antibodies or small molecule inhibitors.5,26
One of the concerns would be that undesired and
unexpected systemic immune disruption might occur
after systemic administration of these agents. The
systemic effect may complicate interpretation of data
obtained for the tumor. LPH nanoparticle-based deliv-
ery system provides a powerful tool to allow local
alteration of a specific molecule/signal without inter-
rupting its systemic functions.15 It also provides the
possibility of studying the effect of tumor microenvir-
onment change without the influence of systemic
perturbation. RT-PCR result confirmed an efficient
down-regulation of TGF-β in the tumor tissues. No
significant change of TGF-βwas observed in the spleen
or lymph nodes (Figure 6B), indicating the absence
of a systemic effect. There was no decrease in body
weight in any treatment groups, suggesting that
there is no toxicity associated with the treatments of
nanoparticles.
Reversed Suppressive Tumor Microenvironment by Silencing
TGF-β. TGF-β regulates immune responses and main-
tains immune homeostasis through its impact on
multiple immune cell lineages.2729 In general, TGF-β
Figure 5. Antitumor activity against different stages of B16F10 melanoma. C57BL/6 mice were inoculated with 2  105
B16F10 cells SC on day 0. LCP vaccinewas given on day 4 (Early vac) or day 13 (Late vac). LPHNP containing siRNA (0.6mg/kg)
against TGF-βwas injected intravenously ondays 13, 15, and17. Tumorgrowth (A, C, D, E) andbodyweight (B)weremeasured
every 2 to 3 days for day 18 days. n = 5, *P< 0. 05, **P< 0. 001. Statistical analyseswere done by comparingwith the untreated
group unless specified with markings.
Figure 6. TGF-β levels after treatments. C57BL/6 mice
were inoculated with 2  105 B16F10 cells SC on day 0,
and received the following treatments: 1, Untreated;
2., LPH(TGF-β); 3, Early vac; 4, LPH(TGF-β) þ Early vac; 5,
Late vac; 6, LPH(TGF-β) þ Late vac. Mice were sacrificed on
day 18; tumor tissues (A) and lymph organs (B) were
harvested forWestern blotting and RT-PCR. For theWestern
blotting, only one representative sample was presented.
For the RT-PCR, n = 5. Statistical analyses were done by
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shows an adverse effect on antitumor immunity and
significantly inhibits tumor immune surveillance.30 We
therefore examined immune cell populations within
the tumor microenvironment to uncover a possible
mechanism governing the enhanced vaccine effects
after tumor-specific silencing of TGF-β. Cell-specific
markers were selected and utilized in both immunos-
taining and quantification with RT-PCR.
Among all the lymphocytes, CD8þ T cells are con-
sidered to be critical effector cells in tumor inhibition
following immunotherapy. It is reported that TGF-β can
suppress CD8þ T cells by inhibiting clonal expansion
and repressing expression of cytotoxic genes.31 We
stained for CD8þ T cells (Figure 7) and found that
despite a similar CTL response was induced after either
vaccination (Figure 3), significantly fewer CD8þ T cells
were observed in tumor tissues after late vaccination
compared with the early one. Silencing of TGF-β in
tumor tissue was able to restore CD8þ T cell numbers
to the same level seen with early vaccination (LPH
(TGF-β)þ Late vac compared with Early vac, P > 0. 05).
Regulatory T (Treg) cells are an important regulator
for maintenance of immunological tolerance by inhib-
iting T cell-mediated immune responses and suppress-
ing autoreactive T cells.32 Tumor Treg cells contribute
to tumor growth by inhibiting tumor-primed CD4þ cell
Figure 7. Tumor infiltration of CD8þ T cells after treatment. B16F10 bearing C57BL/6mice were treatedwith LCP vaccine and
anti-TGF-β siRNA loaded LPHNP as indicated.Micewere sacrificed on day 18, and tumor tissueswere assayed for CD8þ T cells
(red) detection with immunostaining and RT-PCR analysis. The silencing of TGF-β in the late stage tumor reversed the
immunosuppressive tumormicroenvironment and increased the level of CD8þ T cells. n = 5, *P < 0. 05, **P < 0. 001. Statistical
analyses were done by comparing with the untreated group unless specified with markings.
Figure 8. Tumor infiltration of regulatory T cells after treatment. B16F10 bearing C57BL/6micewere treatedwith LCP vaccine
and anti-TGF-β siRNA loaded LPH NP as indicated. Mice were sacrificed on day 18, and tumor tissues were assayed for CD4þ
(green)/Foxp3þ (red) regulatory T cells (yellow) detection with immunostaining and RT-PCR analysis. Silencing of TGF-β
prohibited the infiltration of regulatory T cells in the late stage tumor microenvironment. n = 5, *P < 0. 05, **P < 0. 001.




XU ET AL. VOL. 8 ’ NO. 4 ’ 3636–3645 ’ 2014
www.acsnano.org
3643
activity, suppressing CD8þ T cell activation and hin-
dering DC function.33 TGF-β could induce Foxp3 and
generate induced Treg cells.34 Indeed, an elevated
Treg cell level was seen in the late vaccination group
(Figure 8), correlating with aggressive tumor growth
(Figures 2 and 4). Inhibition of TGF-β depleted the Treg
cells in tumor tissues significantly (Figure 8).
In addition to the lymphoid cells, TGF-β also corre-
lates with the function of some myeloid cells. Myeloid-
derived suppressor cells (MDSCs) suppress antigen-
specific T-cell responses by several distinctmechanisms,
resulting in tumor's escape from immune surveillance.35
Therefore, we are interested in revealing the effect of
TGF-β inhibition on MDSCs. Both immunostaining and
RT-PCR quantification results indicate that there was
no significant change in CD11bþGr-1þ cell level after
treatment (Figure 9). Thus, MDSCs were not responsible
for the enhanced therapy effect by TGF-β siRNA in late
vaccination.
Besides the tumor cells, CD11bþGr-1þ cells, MDSCs
are considered as another major source of immune
suppressive cytokines such as IL-10 and TGF-β. For
future studies, it will be interesting to test whether
down-regulation of TGF-β in both tumor cells and
MDSCs using nanoparticles will generate a more
significant effect compared with present data. Since
TGF-β has multiple functions on multiple cell popula-
tions, it will be also interesting to test whether and how
the specific depleting TGF-β receptors on a single cell
population, such as Treg cells, with targeted nanopar-
ticles would affect the tumor microenvironment.
CONCLUSION
LCP NP-based vaccine elicited a potent systemic
immune response regardless of the existence or stage
of tumors. Targeted silencing of TGF-β expression in
the tumor microenvironment with LPH NP enhanced
the efficacy of the LCP vaccine on an advanced mela-
noma model. Combination of these two nanoparticles
offers a flexible and powerful platform for both mech-
anistic studies and immunotherapeutic strategy devel-
opment.
MATERIALS AND METHODS
Reagents and Murine Cell Line. 1,2-Dioleoyl-3-trimethylammo-
nium-propane chloride salt (DOTAP), dioleoylphosphatydic
acid (DOPA), and 1,2-distearoryl-sn-glycero-3-phosphoethano-
lamine-N-[methoxy(polyethyleneglycol-2000)] ammonium salt
(DSPE-PEG) were purchased from Avanti Polar Lipids. Mannose-
PEG-DSPE was synthesized as described previously,14 and
the structure was confirmed using 1H NMR. DSPE-PEG-AA was
synthesized according to the previously established pro-
tocol.15 H-2Kb restricted peptides Trp2 (SVYDFFVWL, MW 1175),
OVA (SIINFEKL, MW 1773), and modified Trp2 peptide, p-Trp2
(pSpSSSVYDFFVWL,MW1626)were purchased fromPeptide 2.0
(Chantilly, VA). CpGODN 1826 (50-TCCATGACGTTCCTGACGTT-30)
and siRNA against TGF-β (sense, GCAACAACGCCAUCUAUGA;
antisense, UCAUAGAUGGCGUUGUUGC) were obtained from
Sigma-Aldrich (St. Louis, MO). Cholesterol (Chol), hyaluronic
acid (HA), protamine sulfate (fraction x from salmon) and all
the other chemicals were purchased from Sigma Aldrich
(St. Louis, MO), unless otherwise mentioned.
Murine melanoma cell line B16F10 (syngeneic with C57BL/6)
was purchased from ATCC, and cultured in Dulbecco's modified
Eagle medium (Gibco, Invitrogen, Carlsbad, CA) supplemented
with 10% fetal bovine serum (Invitrogen, Carlsbad, CA), 100U/mL
penicillin (Invitrogen), and 100 μg/mL streptomycin (Invitrogen).
Preparation of LCP-Based Vaccine. LCP-based vaccine was pre-
pared as previously described.14 The calcium phosphate (CaP)
core was formed in a water-in-oil microemulsion. Briefly, 600 μL
of 2.5 MCaCl2 containing CpGODN and peptide was added into
Figure 9. Tumor infiltration of MDSCs after treatment. B16F10 bearing C57BL/6mice were treatedwith LCP vaccine and anti-
TGF-β siRNA loaded LPHNP as indicated.Micewere sacrificed on day 18, and tumor tissueswere assayed for CD11bþ (green)/
Gr-1þ (red) MDSCs (yellow) detectionwith immunostaining and RT-PCR analysis. Silencing of TGF-β had negligible impact on
the infiltration of MDSCs in the late stage tumor microenvironment. n = 5. Statistical analyses were done by comparing with
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a 20mLCyclohexane/Igepal CO-520 (71:29, v/v) solution to form
Ca phase. Meanwhile, 600 μL of 12.5 mM Na2HPO4 (pH = 9.0)
and 200 μL of 20 mM DOPA were dispersed into a separate
20 mL oil phase to obtain the phosphate phase. The above two
solutions were mixed and stirred at room temperature for
30 min. Equal volume of ethanol was added to break the
microemulsion. CaP cores were collected with centrifugation
at 10 000g and then washed three times with 20 mL of ethanol
to remove cyclohexane and surfactant. The pellets were dis-
solved in chloroform for further use.
CaP cores were mixed with 200 μL of 20 mM DOTAP/Chol
(1:1), and 20 μL of 20 mM DSPE-PEG-2000/DSPE-PEG-mannose
(1:1) in chloroform. After evaporating the chloroform, LCP
particles were formed by adding 100 μL of 5% glucose.
Preparation of Liposome and LPH. LPH-NP were prepared
through a stepwise self-assembly process based on previously
established protocol.15 DOTAP and Chol (1:1, molar ratio) in
chloroform were mixed, and the solvent was evaporated under
a reduced pressure. Distilled water was added, and the lipo-
somes were extruded sequentially through 400, 200, 100, and
50 nm polycarbonate membranes (Millipore, Billerica, MA) to
form 80100 nm unilamellar liposomes with a final concentra-
tion of 10mMDOTAP and cholesterol. LPH cores were prepared
by mixing 140 μL of solution A (36 μg protamine in 5% glucose)
and 140 μL of solution B (24 μg HA and 24 μg siRNA in 5%
glucose). After incubation at room temperature for 10 min,
60 μL of DOTAP/Chol liposome was added into the LPH cores.
LPH NP was formed and PEGylated by adding 30 μL of DSPE-
PEG (10mg/mL) and 30 μL of DSPE-PEG-AA (10mg/mL) at 50 C
for 15 min. Both final particles were observed using transmission
electron microscopy (JEOL 100CX II TEM, JEOL, Japan). Particle
size and zeta potential were measured with a Malvern Zetasizer
Nano ZS in water (Malvern, Worcestershire, United Kingdom).
Tumor Growth Inhibition. For vaccination studies, 68 weeks
old female C57BL/6 mice were subcutaneously inoculated with
2 105 B16F10 cells on their flank on day 0. In early vaccination
group, LCP vaccine in 5% glucose was injected subcutaneously
into the contralateral side of the inoculation site on day 4. For
late vaccination group, LCP vaccine was given on day 13.
For combined therapy, female C57BL/6 mice of age 68
weeks old were inoculated subcutaneously with 2 105 B16F10
cells on their lower back on day 0. Vaccination was given on
day 4 (early vaccination) or day 13 (late vaccination). LPH NP
containing siRNA (0.6 mg/kg) against TGF-β was injected in-
travenously on day 13, day 15, and day 17 through tail vein.
Tumor size was measured every 2 to 3 days using digital
calipers (Thermo Fisher Scientific, Pittsburgh, PA) and calculated
as (0.5 lengthwidth height). Body weight was also moni-
tored. Humane sacrifice of mice was performed when tumor
reached 20 mm in one dimension.
In Vivo Cytotoxic T Lymphocyte (CTL) Assay. The in vivo CTL assay
was performed on C57BL/6 mice seven days after the vaccina-
tion, according to the previous protocol with slight modi-
fications.36 Splenocytes from naïve C57BL/6 mice were col-
lected and pulsed with either 10 μM Trp2 or Ova peptide in
complete media at 37 C for 1 to 2 h. Both pulsed cell popula-
tions were stained with 2 μM PKH-26 (Sigma-Aldirch, St. Louis,
MO) following the manufacturer's instructions. Then, the Trp2
peptide-pulsed and Ova peptide-pulsed cells were labeled with
4 and 0.4 μMCFSE, respectively. Equal amount of CFSEhigh (Trp2
pulsed cells) and CFSElow (Ova pulsed cells) were mixed and
injected intravenously into the control or immunized mice. After
18 h, splenocytes from these treated mice were collected and
subjected to flowcytometry analysis. Thenumberof CFSEhigh and
CFSElow was calculated, and the in vivo Trp2 specific lysis per-
centage was enumerated according to a published equation.
% specific lysis ¼ (Ova x  Trp2)
(Ova x)  100%
where x ¼ Trp2
Ova
from na__l ve mice
Quantitative RT-PCR. RNA from tissue samples were extracted
with the RNeasy kit (Qiagen) and reverse-transcribed to cDNA
using SuperScript First-Strand Synthesis System for RT-PCR (Life
Technologies). TaqMan Universal PCR Master Mix (Life Tech-
nologies) was mixed with 200 ng of cDNA, and the reactions
were conducted using 7500 Real-Timer PCR System (Life
Technologies). GAPDH was used as an endogenous control.
All the primers for RT-PCR reactions were listed in Table 1. The
data were analyzed with the 7500 Software. The RT-PCR was
performed in triplicates.
Western Blot Analysis. Tumor tissues were collected and lysed
with radioimmunoprecipitation assay (RIPA) buffer. Protein
concentration of the tumor lysates was measured using the
Bradford protein assay reagents following the manufacturer's
instruction. Samples were diluted in 4 sample buffer with
reducing reagent and heated at 95 C for 5 min. After the
electrophoresis on NuPAGE 412% Bis-Tris Gels (Invitrogen,
Grand Island, NY), proteins were transferred to Immobilon-P
transfer membrane (Millipore, Billerica, MA) and probed with
the primary antibody (anti-TGF-β1 mAb (Santa Cruz, Santa
Cruz, CA) or anti-GAPDH mAb (Cell Signaling, Danvers, MA),
respectively) and the horseradish peroxidase-conjugated sec-
ondary antibody. Signals were developed using the Pierce
ECL Western Blotting Substrate (Thermo Fisher Scientific,
Rockford, IL).
Immunofluorescence. Immunofluorescence detection of dif-
ferent cell populations was performed using paraffin sections
of tumor tissues (obtained from the UNC Tissue Procurement
Core). The slides were deparaffinized, antigen recovered, per-
meabilized and fixed if necessary, and blocked with 1% BSA at
room temperature for 1 h. Cell markers were detected with anti-
bodies conjugated with fluorophores (Santa Cruz, Santa Cruz,
CA) as indicated. Images were taken using fluorescence micro-
scopy (Nikon, Tokyo, Japan).
Statistical Analysis. Data were analyzed statistically using a
two-tailed Student's t-test by comparing with the control group
unless specified with markings. Differences were considered
statistically significant if the p value was less than 0.05.
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